Skip to content
Open access

A patient-derived tumoroid platform for NF1 low-grade glioma shows myeloid evolution and shifting metabolic dependencies during in vitro culturing

Aug 2026 · Acta Neuropathologica Communications · 0 citations

TL;DR

The first in vitro tumor-derived spheroid cultures (tumoroids) of 3 NF1-associated LGGs grown for up to 4 weeks that can be passaged and banked are presented, concluding that these NF1 LGG tumoroid cultures have the highest fidelity in the first few weeks of culture, giving a time window to study primary NF1 LGG biology or to assess therapeutic vulnerabilities.

Abstract

About 10–15% of individuals with Neurofibromatosis Type 1 develop a low-grade glioma (LGG) within the optic pathway, and an additional 3–5% of individuals develop LGG outside of the optic pathway. In recent years molecular analysis has greatly enhanced our understanding of what drives these NF1 LGG; however, to date in vitro and in vivo models are rare. Here, we present the first in vitro tumor-derived spheroid cultures (tumoroids) of 3 NF1-associated LGGs grown for up to 4 weeks that can be passaged and banked. To determine how accurately the NF1 LGG tumoroid cultures reflect human disease, and how much and how quickly they drift from the primary tumors, we performed single nuclear RNAseq (snRNA-seq) analysis on primary tumor and 1, 2 and 4 weeks in culture for one of these NF1 LGG tumoroid lines. Observations were confirmed with immunofluorescence staining on all 3 lines. As expected, the few CD3 + T-cells present in the primary tumor are lost by day 14 (IF) and not detected on scRNAseq; macrophages/microglia remain present for at least 14 days but are largely depleted by week 4. Additionally, we observe a shift from more homeostatic microglia in the primary tumor to CD163 positive tumor-associated macrophages/microglia (TAM) in vitro. Neoplastic clusters uniquely associated with the primary tumor had clear upregulation of genes associated with neuronal communication. Our analysis also shows that primary NF1 LGGs rely on the metabolism of fatty acids (FA) for energy, while in vitro, the primary energy source shifts to glucose. Additionally, instead of metabolizing FA, both neoplastic and immune cells switch to FA synthesis in vitro. Finally, we observe a slightly increased proliferative index in vitro versus in vivo, both in neoplastic and immune cells. We conclude that these NF1 LGG tumoroid cultures have the highest fidelity in the first few weeks of culture, giving us a time window to study primary NF1 LGG biology or to assess therapeutic vulnerabilities. Finally, optimizing media conditions, for example to reduce glycolysis and support FA synthesis, could extend the period of highest fidelity for NF1 LGG tumoroids.

Read PDF

Similar papers

Open access Aug 2026

‘An NF2-wildtype malignant meningioma cell line for basic and translational science’

Background Meningiomas are the most common primary nervous system neoplasm in adults. There are few good cellular models, especially of high grade/malignant meningiomas, to use to identify new therapeutic agents and treatment regimens. The widely available, partially characterized, NF2-wildtype (NF2wt) Grade 3 malignan...

Perry Chien, Brendan F. Kohrn, Megan M. Nguyen et al. · 0 citations
Open access Aug 2026

Establishment of a patient-derived malignant peripheral nerve sheath tumor organoid model reveals SHH pathway activation and therapeutic vulnerability

Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive soft tissue sarcoma of presumed peripheral nerve sheath origin, for which effective systemic therapies remain limited. The biological mechanisms underlying its progression and therapeutic vulnerabilities are not fully understood, partly due to the...

Haruki Matsuoka, Keiichi Yoshida, Yukiko Matsuoka et al. · 0 citations
Open access Sep 2026

Pervasive Somatic Mutations in NF1 Drive Cell Type and Spatially Specific Clonal Selection in Neurofibromatosis

Tumorigenesis is a multi-step process shaped by the accumulation of somatic driver mutations, but identifying the earliest steps and cell of origin of tumorigenesis remains challenging. Single cell genomics in >1.7 million single cells across donors with the cancer predisposition syndrome neurofibromatosis type 1 (NF-1...

D. Snellings, Kow Essuman, Benjamin Finander et al. · 0 citations
Open access Aug 2026

IN SILICO STUDY ON PEDIATRIC HIGH-GRADE GLIOMAS

Pediatric High-Grade Gliomas (pHGGs) encompass a group of emerging glial cell tumors characterized by their rare and aggressive nature with unpromising therapeutic prospects. Studies on pediatric glial tumors have revealed specific mutations related to histone variants, TP53 (Tumor Protein 53), and growth factors, diff...

Raquel Furlani Rocon Braga, Matheus Correia Casotti, L. S. C. Altoé et al. · 0 citations
Open access Sep 2026

Patient-Derived Glioma Models Preserve Tumor Heterogeneity and Identify Stearoyl-CoA Desaturase1 (SCD1) as a Candidate Biomarker for Precision Immunotherapy

Background Pediatric and adult brain tumors, including glioblastoma, astrocytoma, ependymoma, and medulloblastoma, remain associated with poor prognosis despite advances in surgery, radiation, and chemotherapy. Therapeutic resistance, tumor heterogeneity, and treatment-related toxicity highlight the need for clinically...

Margarita Gutova, Eric Ma, H. Natri et al. · 0 citations
Sep 2026

Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes.

BACKGROUND Oligodendroglioma is a primary central nervous system tumor classified by the presence of isocitrate dehydrogenase (IDH) mutations and codeletion of 1p/19q. A lack of faithful preclinical model systems for this disease has limited progress in understanding the biology of this genetically unique subtype of ad...

Ipsita G. Kundu, Nicolas Toro, Aaron Y. Mochizuki et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.